Lv3
220 积分 2024-05-08 加入
什么时候才能不上班
Safety, pharmacokinetics (PK), and clinical efficacy of ICP-723, a highly selective next-generation pan-TRK inhibitor, in patients with solid tumor
23分钟前
求助中
Safety, pharmacokinetics (PK), and clinical efficacy of ICP-723, a highly selective next-generation pan-TRK inhibitor, in patients with solid tumor
1小时前
求助中
Abstract 6187: ICP-723 is a potent pan-TRK Inhibitor with robust anti-tumor activities against wild-type and acquired drug-resistant mutations of NTRK fusions
1小时前
求助中
Identification of a novel ADCC-related gene signature for predicting the prognosis and therapy response in lung adenocarcinoma
1天前
已完结
At the interface of tumor-associated macrophages and fibroblasts: immune-suppressive networks and emerging exploitable targets
1天前
已完结
Antitumour immunity regulated by aberrant ERBB family signalling
4天前
已完结
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
17天前
已完结
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial
17天前
已完结
Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial
28天前
已完结
Cancer vaccines: the next immunotherapy frontier
28天前
已完结
皖公网安备34019202002308
